| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Precigen Inc. | PRGN-2009 in combination with pembrolizumab | Newly diagnosed patients with HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) | Phase 2 | Ongoing | Intravenous | Oncology |
| PRF Technologies Ltd. | PRF-110 | Bunionectomy | Phase 3 | Data Released | Topical | Orthopedic |
| Processa Pharmaceuticals Inc. | PCS499 | Necrobiosis Lipoidica (NL) | Phase 2b | Ongoing | oral | #N/A |
| Processa Pharmaceuticals Inc. | NGC-Gemcitabine (PCS3117) | Solid tumors | Phase 2b | Trial Discontinued | oral | Oncology |
| Processa Pharmaceuticals Inc. | NGC-Capecitabine (PCS6422) | Breast cancer | Phase 2 | Data Released | Oral | Oncology |
| Processa Pharmaceuticals Inc. | PCS12852 | Gastroparesis | Phase 2a | Oral | Gastroenterology | |
| ProKidney Corp. | Rilparencel (REGEN-006) - (PROACT 1) | Type 2 Diabetes | Phase 3 | Ongoing | Oral | Endocrinology |
| ProKidney Corp. | REGEN-008 - (REACT follow up) | Chronic kidney disease (CKD) | Phase 3 | Enrollment Initiation | intravenous | N/A |